AFX 9154Alternative Names: AFX-9154
Latest Information Update: 24 Jun 2008
At a glance
- Originator Afecta Pharmaceuticals
- Class Proteins
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Clinical Phase Unknown Leukaemia
Most Recent Events
- 24 Jun 2008 Clinical trials in Leukaemia in USA (unspecified route)